addressing psoriasis at the molecular level

 
 
 
Stock image of chimicals in a lab.jpg
 
 

A BETTER TREATMENT & MARKET OPPORTUNITY


Many therapies treat the inflammation of psoriasis by targeting parts of the immune system. While effective, this approach can result in systemic adverse effects. Recensa is taking a different approach. Recensa is targeting oxidative stress, an important factor in the ongoing inflammatory cycle of psoriasis. By activating Nrf2, our investigational small molecule pharmaceuticals can upregulate up to 300 anti-oxidant molecules and reduce oxidative stress within the cells. This reduces the markers of inflammation of psoriasis within the cells of the skin.

 
 
 
 

tHE NEED FOR BETTER THERAPIES

Millions of those with psoriasis suffer from poor productivity, impaired social relationships, and damaged self-perceptions

THE PSORIASIS MARKET

~7.5 million patients in the United States

-$63.2 billion in direct medical costs

-90% of patients affected by mild-to-moderate psoriasis

 
 

EXISTING TREATMENTS FALL SHORT

TOPICAL CORTICOSTEROIDS

Corticosteroids are effective at suppressing inflammation. However, they can cause significant adverse effects and have limitations on use in certain body parts. Corticosteroids are also not recommend for long term use, and according to several scientific studies, result in only low to moderate satisfaction. 

VITAMIN D ANALOGS

Vitamin D analogs have moderate efficacy in symptom relief, and, similar to corticosteroids, carry limitations on use in certain body parts. While patients report moderate satisfaction, Vitamin D analogs fail to address psoriasis extensively at the molecular level as Recensa's Nrf2 activators do. 

 
 
 

RECENSA'S unique approach: Nrf2 activation

 
Molecular makeup of an atom.jpg
 
 

UPREGULATION OF Nrf2


THE MASTER CONTROLLER FOR ANTIOXIDANTS withIN THE CELL

Nrf2 is a transcription factor, a type of protein that influences how genetic information is used to produce other proteins. Nrf2 regulates the expression of antioxidant proteins that protect against  oxidative damage triggered by injury and inflammation.  While normally bound to other proteins, Nrf2 is released into the cell nucleus under conditions of oxidative stress. Research has shown that increasing levels of Nrf2 may be useful for treating diseases that are caused by, or involve, oxidative stress. These include multiple sclerosis, fibrotic liver disease, and many inflammatory diseases, most notably psoriasis.

a BETTER THERAPy is here

Nrf2 has been identified as a key regulator of the antioxidant response in human cells. When activated, it stimulates the release of up to 300 antioxidant molecules. Our developmental topical therapies have been shown in skin models to reduce markers of psoriasis.

Potential benefits of Nrf2 ACTIVATORS

  • Potent efficacy

  • Fewer adverse effects

  • Use on all parts of the body

  • Expected high patient satisfaction

In Psoriasis, multiple inflammatory cytokines cause oxidative stress

In Psoriasis, multiple inflammatory cytokines cause oxidative stress

Nrf2 works within the nucleus to stimulate the production of multiple types of anti-oxidant proteins

Nrf2 works within the nucleus to stimulate the production of multiple types of anti-oxidant proteins

 
 

see our development plan

Recensa's strategic 3 year development plan to ind application 

 
strategy.jpg